|Day Low/High||78.39 / 79.11|
|52 Wk Low/High||67.88 / 88.16|
Pfizer may not be the best investment in coming months, as doubts surface about the company's near-term prospects in the absence of M&A.
National, three-year program kicks off in 15 cities across the U.S.
In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Eli Lilly & Co. has taken over the #98 spot from NextEra Energy Inc , according to ETF Channel.
Eli Lilly shares are 4.7% lower than a year ago. When the company reports earnings on Oct. 25, investors will be looking for something to move the stock.
Bad enough Tyson faces a class-action lawsuit over poultry pricing. It's also been downgraded by an equity research firm you've never heard of but big hedge funds sure have.
A class-action lawsuit over poultry pricing could result in substantial damages for Tyson Foods, analyst says.
Chi-Med may be pressing ahead with a series of late-stage oncology drug trials, but it is anything but a one-trick pony biotech company.
A crude oil rally helps Wall Street rally on Wednesday to erase all losses endured a day earlier.
Stocks are higher on Wednesday as crude oil prices near the psychologically important $50 level.
Stocks climb on Wednesday as crude oil prices nears the psychologically-important $50 level.
Eli Lilly (LLY) is buying drugmaker Boehringer Ingelheim's portfolio of pet vaccines for $885 million and a manufacturing and research site in Fort Dodge, IA.
Stock futures move higher on Wednesday morning after a read on the labor market shows 154,000 jobs added to private payrolls in the U.S. in September.
Deal Subject to FTC Approval and Successful Closing of BI/Sanofi Asset Swap
The Danish pharmaceuticals maker is facing tighter margins and tougher competition in the U.S.
Cramers is avoiding Nike and loves Newell so much he bought the company for Action Alerts PLUS.
The stocks we thought would be the strongest in 2016 are now losing their footing, Cramer says.
Eli Lilly (LLY) was upgraded to 'buy' from 'neutral' on Tuesday at Goldman Sachs.
Goldman Sachs upped Eli Lilly's (LLY) stock rating to 'buy' this morning, citing its solid pipeline.
Here are Tuesday's top research calls, including upgrades for AutoZone and Eli Lilly, and downgrades for J.M. Smucker and Toll Brothers.
One of the largest healthcare companies in the world embraces Salesforce to gain more insights about their patients and quickly build and release apps based on their needs
Rumors are swirling about Big Pharma interest in the cancer drug developer, but the validity of such theories is questioned by at least some company followers.
UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.
I want to use a marriage of stock and ratio call spreads to create a juiced-up, covered-call approach.
Allegations that Merck breached patents on diabetes blockbuster Lantus looks like a replay of Sanofi's 2015 case against Eli Lilly.